Angle (AGL) RNS Announcements

Add to Alert list
Date Time Source Announcement
11 Jan 2023 05:20 PM
RNS
Holding(s) in Company
10 Jan 2023 06:20 PM
RNS
Holding(s) in Company
06 Jan 2023 11:05 AM
RNS
Second Price Monitoring Extn
06 Jan 2023 11:00 AM
RNS
Price Monitoring Extension
05 Jan 2023 09:05 AM
RNS
Second Price Monitoring Extn
05 Jan 2023 09:00 AM
RNS
Price Monitoring Extension
05 Jan 2023 07:01 AM
RNS
Appointment of Non-Executive Director
05 Jan 2023 07:00 AM
RNS
Business Update
12 Dec 2022 07:00 AM
RNS
Two Parsortix posters presented at SABCS
02 Dec 2022 05:30 PM
RNS
Issue of Equity
02 Nov 2022 07:00 AM
RNS
Multiple downstream analysis techniques for CTCs
01 Nov 2022 04:41 PM
RNS
Second Price Monitoring Extn
01 Nov 2022 04:35 PM
RNS
Price Monitoring Extension
24 Oct 2022 07:00 AM
RNS
Parsortix poster presented at ISLB meeting
21 Oct 2022 06:15 PM
RNS
Issue of Equity
18 Oct 2022 07:00 AM
RNS
Streamlining of operations to increase cash runway
17 Oct 2022 02:23 PM
RNS
TR-1: Notification of major holdings
12 Oct 2022 07:00 AM
RNS
First regional distribution agreement
30 Sep 2022 05:30 PM
RNS
Holding(s) in Company
30 Sep 2022 05:30 PM
RNS
Issue of Equity
29 Sep 2022 07:00 AM
RNS
Interim Results
29 Sep 2022 07:00 AM
RNS
Positive headline results from ovarian study
28 Sep 2022 07:00 AM
RNS
Study using Parsortix in head and neck cancer
13 Sep 2022 07:00 AM
RNS
New poster presented at ASCP Meeting
12 Sep 2022 07:30 AM
RNS
Novel assay predicts malignancy in pelvic mass
01 Sep 2022 07:00 AM
RNS
Notice of Interim Results and Webcast
28 Jul 2022 07:00 AM
RNS
Novel insight into metastasis in NSCLC patients
20 Jul 2022 02:33 PM
RNS
Holding(s) in Company
20 Jul 2022 07:00 AM
RNS
NEW STUDY OF PARSORTIX SYSTEM IN NSCLC
19 Jul 2022 10:00 AM
RNS
Director/PDMR Shareholding
15 Jul 2022 07:00 AM
RNS
Results of Capital Raise
14 Jul 2022 05:24 PM
RNS
Retail Offer via PrimaryBid
14 Jul 2022 05:23 PM
RNS
Proposed Placing and Retail Offer
08 Jul 2022 05:30 PM
RNS
Issue of Equity
29 Jun 2022 04:35 PM
RNS
Result of 2022 Annual General Meeting
27 Jun 2022 07:00 AM
RNS
Spread of breast cancer accelerates during sleep
23 Jun 2022 06:24 PM
RNS
Issue of Equity
22 Jun 2022 07:00 AM
RNS
Secured contract from pharma services customer
16 Jun 2022 07:00 AM
RNS
Predicting immunotherapy response in SCLC
14 Jun 2022 07:00 AM
RNS
Potential role of invasive cellular protrusions
30 May 2022 07:00 AM
RNS
Partnership with major United States urology group
27 May 2022 07:00 AM
RNS
Molecular characterisation of CTCs
25 May 2022 04:35 PM
RNS
Price Monitoring Extension
25 May 2022 12:30 PM
RNS
ANGLE receives FDA clearance for Parsortix
20 May 2022 07:00 AM
RNS
Prostate Cancer UK funds new study using Parsortix
28 Apr 2022 07:00 AM
RNS
Preliminary Results
20 Apr 2022 07:00 AM
RNS
Notice of Preliminary Results and Webcast
14 Apr 2022 07:00 AM
RNS
Poster on Parsortix system presented at AACR 2022
01 Apr 2022 07:00 AM
RNS
Identifying drug targets in cancer metastasis
29 Mar 2022 07:00 AM
RNS
Rapid information on patient response to therapies

ANGLE PLC is a commercially driven specialist medical diagnostic company with pioneering products in cancer diagnostics and foetal health. The Company's product includes Parsortix cell separation system.

Founded in 1994, Angle listed on LSE in 2004 under the ticker AGL.

UK 100

Latest directors dealings